Nav: Home

A tumor cell population responsible for resistance to therapy and tumor relapse

October 08, 2018

Resistance to therapy is a major problem in cancer patients as the cells that resist to therapy is at the root of tumour relapse and is associated with high morbidity and mortality. A better understanding of the mechanisms associated with resistance to therapy is essential for the development of better strategies to definitively eradicate cancer and prevent tumour relapse.

In a study published in Nature, researchers lead by Pr. Cédric Blanpain, MD/PhD, WELBIO investigator and Professor at the Université libre de Bruxelles, Belgium identified a population of tumour cells that persist following drug treatment, leading to cancer relapse following treatment discontinuation in basal cell carcinoma, the most frequent skin cancer. The study also identifies a combination of drugs that can eliminate this the tumor population that resists to the therapy and prevents tumour relapse after treatment discontinuation.

Basal cell carcinoma is the most common human cancer, affecting several millions of new patients each year across the world. Vismodegib, a FDA approved drug is used for the treatment of locally advanced and metastatic basal cell carcinoma in humans. Many patients treated with vismodegib experience tumour regression during treatment, but very often their tumours relapse following treatment discontinuation. The precise mechanisms involved in tumour regression upon vismodegib administration and how the tumour cells resist to the therapy leading to cancer relapse are poorly understood.

In this new study, Adriana Sánchez-Danés - Université libre de Bruxelles, ULB, Laboratory of Stem Cells and Cancer - and colleagues identified the mechanism by which vismodegib leads to tumor regression and uncovered the origin of the relapse observed upon treatment discontinuation. They found that vismodegib promotes the differentiation of the bulk of tumour cells, leading to their elimination. Vismodegib treatment led to the emergence of population of dormant tumour cells characterized by active Wnt signaling that persists despite continuous drug administration.

In collaboration with the groups of Pr. Tabernero (Barcelona, Spain) and Pr. del Marmol (Brussels, Belgium), the researchers demonstrated that this population of tumor cell population active for Wnt signaling was also found in patients with basal cell carcinoma treated with vismodegib.

Adriana Sánchez-Danés and colleagues found that inhibition of Wnt signaling together with Vismodegib eliminates the persisting tumor lesions leading to tumor eradication in the vast majority of the cases. "It was really exciting to identify a combination of drugs already available in clinics that lead to the eradication of resisting tumor cells and avoiding tumor relapse in the most frequent cancer in humans", comments Adriana Sánchez-Danés, the first author of the study.

Altogether, this study illustrates that vismodegib promotes tumour regression by promoting the differentiation of tumour cells. This demonstrates for the first time that inducing tumour differentiation is a safe and efficient strategy to treat solid tumours such as basal cell carcinoma. « This is the first example of a FDA approved drug used to treat solid tumor that induces tumor regression through differentiation. Tumor differentiation is an exciting route to treat cancer as it is non toxic for normal cells and was proved to be a revolutionary treatment in certain Leukemia» said Cédric Blanpain, the senior author of study. « Our study also identifies a new mechanism of resistance to therapy in basal cell carcinoma and demonstrates that the administration of two existing drugs is sufficient to prevent tumor relapse in the vast majority of the cases. The next step would be to conduct clinical trials using the combination of these two drugs in patients with relapsing basal cell carcinomas and possibly other cancers characterized by the activation of the two signaling pathways identified here", explains Cédric Blanpain, the corresponding author of the Nature paper.
-end-


Université libre de Bruxelles

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
More Cancer News and Cancer Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#543 Give a Nerd a Gift
Yup, you guessed it... it's Science for the People's annual holiday episode that helps you figure out what sciency books and gifts to get that special nerd on your list. Or maybe you're looking to build up your reading list for the holiday break and a geeky Christmas sweater to wear to an upcoming party. Returning are pop-science power-readers John Dupuis and Joanne Manaster to dish on the best science books they read this past year. And Rachelle Saunders and Bethany Brookshire squee in delight over some truly delightful science-themed non-book objects for those whose bookshelves are already full. Since...
Now Playing: Radiolab

An Announcement from Radiolab